OncoCyte Corp. Hits New 52-Week High of $6.76, Up 146.47%

OncoCyte Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 6.76 on October 24, 2025. This achievement marks a remarkable increase of 146.47% over the past year, significantly outperforming the S&P 500, which has seen a gain of 16.9% during the same period. With a market capitalization of USD 71 million, OncoCyte operates in a competitive industry characterized by innovation and rapid advancements. Despite its current loss-making status, indicated by a negative price-to-earnings ratio, the company has demonstrated resilience and growth potential. The stock's previous 52-week low was recorded at USD 1.92, highlighting the substantial upward movement in its price. Investors and market observers will be keen to monitor how OncoCyte Corp. continues to navigate the evolving landscape of the pharmaceuticals and biotechnology industry, especially following this notable price achievement.